SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Stake in Evaxion Biotech A/S

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.99% in Evaxion Biotech A/S as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Evaxion Biotech A/S.
• As of March 31, 2025, the Reporting Persons beneficially own an aggregate of 310,441 American Depositary Shares (ADS) of Evaxion Biotech A/S.
• This ownership represents 4.99% of the total class of American Depositary Shares.
• Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of these shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is also deemed to beneficially own the securities.
• Both Armistice Capital, LLC and Steven Boyd hold shared voting power and shared dispositive power over all 310,441 shares.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing no positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant, but non-controlling, passive investment by Armistice Capital, LLC and Steven Boyd in Evaxion Biotech A/S. Such filings are standard disclosures required by the SEC when an entity or individual acquires more than 5% of a company's voting shares, or in this case, an amendment to a previous filing. For biotech companies, institutional ownership can signal investor confidence, though a 13G specifically denotes a passive investment intent, differentiating it from an activist stake (which would typically be filed under Schedule 13D).

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
• Investment Professionals: Offers insight into the holdings of Armistice Capital, LLC and Steven Boyd, potentially signaling their investment thesis or interest in the biotech sector.

Key Dates

Keywords

Evaxion Biotech A/S, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, SEC Filing, American Depositary Shares, Investment Management, Institutional Ownership